Risk Factors Associated with a First Exacerbation Among Patients with COPD Classified as GOLD A and B in Routine Clinical Practice in the UK

被引:0
|
作者
Rothnie, Kieran J. [1 ,7 ]
Numbere, Beade [1 ]
Gelwicks, Steven [2 ]
Lu, Yifei [1 ,3 ]
Sharma, Raj [4 ]
Compton, Chris [4 ]
Ismaila, Afisi S. [2 ,5 ]
Quint, Jennifer K. [6 ]
机构
[1] GSK, Value Evidence & Outcomes, R&D Global Med, London, England
[2] GSK, Value Evidence & Outcomes, R&D Global Med, Collegeville, PA USA
[3] Univ North Carolina Chapel Hill, Dept Epidemiol, Chapel Hill, NC USA
[4] GSK, Global Med, London, England
[5] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada
[6] Imperial Coll London, Natl Heart & Lung Inst, London, England
[7] GSK, Value Evidence & Outcomes, R&D Global Med, 980 Great West Rd, Brentford TW8 9GS, Middlesex, England
关键词
COPD; CPRD; exacerbation; GOLD A/B; risk factor; UK; OBSTRUCTIVE PULMONARY-DISEASE; HEALTH-CARE; PREDICTION; OUTCOMES;
D O I
10.2147/COPD.S413947
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Purpose: Risk factors for exacerbations of chronic obstructive pulmonary disease (COPD) have been previously characterized for patients with more severe cases of COPD. It is unclear how the risk of first exacerbation may best be identified in patients with less severe disease. This study investigated risk factors for first exacerbation among English patients with COPD classified as Global Initiative for Chronic Obstructive Lung Disease (GOLD) group A or B. Patients and Methods: A retrospective cohort study using data from the UK Clinical Practice Research Datalink (CPRD) AURUM linked to Hospital Episode Statistics. Patients with COPD aged >= 35 years and classified as GOLD group A or B (2020 criteria) from January 2013-December 2019 were eligible. Patients were required to have 24 months history in CPRD (baseline). Two cohorts were defined: cohort 1 included patients with no severe exacerbations during baseline; cohort 2 included patients with no moderate or severe exacerbations during baseline. Risk factors associated with severe, or combined moderate and severe exacerbation were examined for up to 5 years of follow-up. Results: Overall, 194,948 patients were included in cohort 1 (mean age 66.2 years; 55.2% male), and 148,396 patients in cohort 2 (mean age 66.1 years; 56.6% male). Identified risk factors for exacerbation (and associated 1-year absolute risk of severe, or combined moderate and severe exacerbation, respectively) included: Medical Research Council dyspnea scale score (15.9%/28.4%); COPD Assessment Test score (9.6%/25.3%); GOLD grade of airflow limitation (forced expiratory volume in 1 second % predicted; 13.6%/27.5%); and lung cancer (8.1%/23.6%). After adjustment for risk factors, these factors remained independently associated with severe exacerbation at 1, 3, and 5 years of follow-up. Conclusion: The identified risk factors may aid physicians in the early recognition of patients with COPD classified as GOLD group A or B at risk of first exacerbation.
引用
收藏
页码:2673 / 2685
页数:13
相关论文
共 50 条
  • [31] A Study of Risk Factors Associated with Diabetic Foot, Knowledge and Practice of Foot Care among Diabetic Patients
    Naicker, Amaramalar Selvi
    Ohnmar, Htwe
    Choon, Soon Kong
    Yee, Kanddy Lou Chin
    Naicker, Manimalar Selvi
    Das, Srijit
    Roohi, Syed Ahmad
    INTERNATIONAL MEDICAL JOURNAL, 2009, 16 (03): : 189 - 193
  • [32] Cataract in Patients with Diabetes Mellitus - Incidence Rates in the UK and Risk Factors Based on the Clinical Practice Research Datalink (CPRD)
    Becker, Claudia
    Schneider, Cornelia
    Aballea, Samuel
    Bailey, Clare
    Bourne, Rupert
    Jick, Susan
    Meier, Christoph
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 : 78 - 78
  • [33] Factors associated with the prescription of inhaled corticosteroids in GOLD group A and B patients with COPD - subgroup analysis of the Taiwan obstructive lung disease cohort
    Wei, Yu-Feng
    Kuo, Ping-Hung
    Tsai, Ying-Huang
    Tao, Chi-Wei
    Cheng, Shih-Lung
    Lee, Chao-Hsien
    Wu, Yao-Kuang
    Chen, Ning-Hung
    Hsu, Wu-Huei
    Hsu, Jeng-Yuan
    Lin, Ming-Shian
    Wang, Chin-Chou
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2015, 10 : 1951 - 1956
  • [34] NSAIDs and risk of myocardial infarction in patients with no major risk factors: A nested case-control study in the UK Clinical Practice Research Datalink
    Baak, Brenda N.
    Jick, Susan S.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 282 - 282
  • [35] Risk of adverse outcomes during gabapentinoid therapy and factors associated with increased risk in UK primary care using the clinical practice research datalink: a cohort study
    Muller, Sara
    Bailey, James
    Bajpai, Ram
    Helliwell, Toby
    Harrisson, Sarah A.
    Whittle, Rebecca
    Mallen, Christian D.
    Ashworth, Julie
    PAIN, 2024, 165 (10) : 2282 - 2290
  • [36] Treatment Outcomes With First-line Therapies With Entecavir and Tenofovir in Treatment-Naive Chronic Hepatitis B Patients in a Routine Clinical Practice
    Ha, Nghiem B.
    Trinh, Huy N.
    Rosenblatt, Lisa
    Nghiem, Dat
    Nguyen, Mindie H.
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2016, 50 (02) : 169 - 174
  • [37] Factors associated with improvement in ejection fraction in clinical practice among patients with heart failure: Findings from IMPROVE HF
    Wilcox, Jane E.
    Fonarow, Gregg C.
    Yancy, Clyde W.
    Albert, Nancy M.
    Curtis, Anne B.
    Heywood, J. Thomas
    Inge, Patches Johnson
    McBride, Mark L.
    Mehra, Mandeep R.
    O'Connor, Christopher M.
    Reynolds, Dwight
    Walsh, Mary Norine
    Gheorghiade, Mihai
    AMERICAN HEART JOURNAL, 2012, 163 (01) : 49 - U72
  • [38] Influence of prognostic factors on outcomes among metastatic breast cancer patients treated with CDK4&6 inhibitors in routine clinical practice
    Saverno, K. R.
    Carter, G. C.
    Li, L.
    Battiato, L. A.
    Huang, Y-J
    Smyth, E. N.
    Price, G. L.
    Sheffield, K. M.
    Baxi, S. S.
    Kuk, D.
    Seidman, A. D.
    CANCER RESEARCH, 2019, 79 (04)
  • [39] Clinical features and risk factors associated with morbidity and mortality among patients with COVID-19 in northern Ethiopia
    Abraha, Hiluf Ebuy
    Gessesse, Zekarias
    Gebrecherkos, Teklay
    Kebede, Yazezew
    Weldegiargis, Aregawi Weldegebreal
    Tequare, Mengistu Hagazi
    Welderufael, Abadi Luel
    Zenebe, Dawit
    Gebremariam, Asqual Gebreslassie
    Dawit, Tsega Cherkos
    Gebremedhin, Daniel Woldu
    de Wit, Tobias Rinke
    Wolday, Dawit
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2021, 105 : 776 - 783
  • [40] Presence of Risk Factors Associated With Colectomy Among Patients With Colectomy in the Tofacitinib OCTAVE Ulcerative Colitis Clinical Program
    Rubin, David T.
    Salese, Leonardo
    Kotze, Paulo G.
    Woolcott, John C.
    Su, Chinyu
    Mundayat, Rajiv
    Paulissen, Jerome
    Torres, Joana
    Long, Millie
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S696 - S697